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Structured Abstract 
Aim: To assess the diagnostic accuracy of the FINDRISC for undiagnosed type 2 diabetes 
mellitus (T2DM) and dysglycaemia (i.e. the presence of prediabetes or T2DM) among early 
middle-aged adults from vulnerable groups in a large-scale European cohort. 
Methods: Participants were recruited from low-socioeconomic areas in high-income 
countries (HICs) (Belgium-Finland) and in HICs under austerity measures (Greece-Spain) and 
from the overall population in low/middle-income countries (LMICs) (Bulgaria-Hungary). 
Study population comprised of 2,116 parents of primary-school children from families 
identified at increased risk of T2DM, based on parental self-reported FINDRISC. Sensitivity 
(Se), specificity (Sp), area under the receiver operating characteristic curves (AUC-ROCs) and 
the optimal cut-offs of FINDRISC that indicate an increased probability for undiagnosed 
T2DM or dysglycaemia were calculated. 
Results: The AUC-ROC for undiagnosed T2DM was 0.824 with optimal cut-off≥14 (Se=68%, 
Sp=81.7%) for the total sample, 0.839 with optimal cut-off≥15 (Se=83.3%, Sp=86.9%) for 
HICs, 0.794 with optimal cut-off≥12 (Se=83.3%, Sp=61.1%) for HICs under austerity measures 
and 0.882 with optimal cut-off≥14 (Se=71.4%, Sp=87.8%) for LMICs. The AUC-ROC for 
dysglycaemia was 0.663 with optimal cut-off≥12 (Se=58.3%, Sp=65.7%) for the total sample, 
0.656 with optimal cut-off≥12 (Se=54.5%, Sp=64.8%) for HICs, 0.631 with optimal cut-off≥12 
(Se=59.7%, Sp=62.0%) for HICs under austerity measures and 0.735 with optimal cut-off≥11 
(Se=72.7%, Sp=70.2%) for LMICs.  
Conclusion: FINDRISC can be applied for screening primarily undiagnosed T2DM but also 
dysglycaemia among vulnerable groups across Europe, considering the use of different cut-
offs for each subpopulation.  
Keywords: Type 2 diabetes mellitus; FINDRISC; Diabetes screening; Diabetes prevention; 
Vulnerable groups 
Abbreviation list:  
BMI: Body Mass Index 
FINDRISC: Finnish Diabetes Risk Score 
FPG: Fasting plasma glucose 
T2DM: Type 2 Diabetes Mellitus 
HICs: High-income countries 
IFG: Impaired fasting glucose 
IGT: Impaired glucose tolerance 
LMICs: Low/middle-income countries 
OGTT: Oral glucose tolerance test 
ROC: Receiver Operating Characteristic 
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1. Introduction 
Diabetes mellitus is one of the largest global health emergencies of the 21st century, with 
increasing prevalence worldwide, that currently affects 8.8% of the adult population [1]. 
Type 2 diabetes mellitus (T2DM) accounts for about 90% of all diabetes cases, while a major 
public-health challenge is that about 50% of these cases remain undiagnosed [1]. Since 
T2DM does not cause specific symptoms for many years, detection is often delayed and 
advanced complications are frequently present at the time of diagnosis [2, 3]. In addition, 
prediabetes -i.e. an intermediate hyperglycemic state characterized by impaired fasting 
glucose (IFG) and/or impaired glucose tolerance (IGT)- is a risk factor for developing T2DM 
with the annual incidence of T2DM in individuals with different prediabetes stages (IFG, IGT, 
and both) to vary from 5 to 10%[4]. As there is evidence that early detection of T2DM may 
reduce mortality and the risk of complications [5, 6], and that the identification of people 
with prediabetes followed by lifestyle and/or pharmacological interventions can prevent or 
delay T2DM [7, 8], the implementation of screening strategies for its early diagnosis and 
prevention is reasonable [9].  
There is a variation in the burden of diabetes among population groups. About 79% of adults 
with diabetes live in low/middle-income countries (LMICs) [1], while low educational level 
and high unemployment rate in high income countries (HICs) have been associated with 
increased risk of T2DM [10]. Moreover, 84.5% of all people with undiagnosed diabetes live in 
LMICs, while even in HICs 37.3% of people with diabetes have undiagnosed disease [1]. 
These inequalities may also further vary among HICs, since the global financial crisis has an 
adverse impact on population health and access to care; especially in countries that suffered 
the strictest austerity measures [11]. Thus, a large segment of the population in LMICs, as 
well as low socioeconomic groups in HICs could be considered as vulnerable for developing 
T2DM. Given the increasing T2DM prevalence [1], identifying T2DM at early stage becomes a 
public health priority, especially in vulnerable population groups.  
According to the current guidelines, T2DM diagnosis can be based on measurements of 
either fasting plasma glucose (FPG), 2h glucose value after an oral glucose tolerance test 
(OGTT) or glycated haemoglobin (HbA1c) [12, 13]. However, these methods are invasive, 
time-consuming and expensive [14], hence not suitable for mass screening. Furthermore, 
since they provide information only by measuring glycaemia, it would be more efficient to 
also identify individuals at high risk of T2DM when being in normoglycaemic state, in order 
to prevent prediabetes and overt T2DM by implementing effective interventions. Thus, a 
number of risk scores have been developed worldwide from different settings and 
populations, both for detection of undiagnosed T2DM and for identification of individuals at 
future risk [15-17]. In this context, international health organizations [12, 13, 18] 
recommend the use of validated diabetes risk scores to guide health care professionals on 
whether performing a diagnostic test is appropriate.  
The Finnish Diabetes Risk Score (FINDRISC) was developed for the Finnish National T2DM 
Prevention Programme [19] to facilitate identification of people at increased risk and it is the 
most commonly used diabetes risk score in Europe. Previous studies have evaluated the 
FINDRISC in detecting undiagnosed T2DM and/or prediabetes in many European [20-26] and 
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other countries [27-31], with good validity results in most of these populations. Simplified 
versions of the FINDRISC have been also tested and were found to be equally efficient as 
FINDRISC [22, 25, 28]. However, previous validation studies of the FINDRISC conducted in 
Europe are based on data collected from one country and have not taken into consideration 
socioeconomic criteria or focused on vulnerable groups. Furthermore, the study population 
in these studies included middle-aged or old participants [20-26] or patients with one or 
more cardiovascular risk factors [21, 22, 26], usually recruited using opportunistic screening 
methods (i.e. among those individuals attending general practitioners’ offices or health care 
centres) [21, 23, 26] or as a random population sample [20, 22, 24, 25]. Thus community-
based evaluations of the FINDRISC among vulnerable groups in multi-centre studies seem to 
be essential in order to examine its general applicability and accuracy to screen for glucose 
metabolism disorders, as well as to provide a rational basis to refer high risk individuals for 
glycaemia testing so that to confirm diagnosis. 
The primary aims of current study were to (i) assess the diagnostic accuracy of the FINDRISC 
in detecting undiagnosed T2DM and dysglycaemia among early middle-aged adults in a 
large-scale European cohort and (ii) examine any potential differences in FINDRISC 
performance among LMICs and vulnerable groups in HICs and HICs under austerity 
measures. A secondary aim was to examine which FINDRISC components were most strongly 
associated with these outcomes, so that to further support the development and use of 
simplified versions.  
2. Material and methods 
2.1. Study background 
The current study used the baseline data of the EU-funded Feel4diabetes-study 
(http://feel4diabetes-study.eu/), which aimed to develop, implement and evaluate a school- 
and community-based intervention to prevent T2DM among families from vulnerable groups 
across Europe. The Feel4Diabetes-study was registered at clinicaltrials.gov as NCT02393872. 
2.2. Study protocol and recruitment 
A detailed description of methods has been previously published [32]. In brief, recruitment 
was based on a standardized, multi-stage sampling procedure and was conducted within 
selected provinces in six European countries, targeting population-groups that were 
vulnerable for developing T2DM. In Bulgaria and Hungary (i.e. LMICs), all families were 
considered vulnerable and eligible to participate in the study, while in Belgium, Finland, 
Greece and Spain (i.e. HICs), families from municipalities with the lowest educational level or 
the highest unemployment rate (as retrieved from official resources and authorities) were 
included as vulnerable groups. In each country, primary schools located in the selected 
municipalities were used as the entry-point to the community and the children attending the 
first three grades of compulsory education, as well as their parents and/or grandparents, 
were recruited to the study.  
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Self-administrated FINDRISC questionnaires were collected from 20,547 parents (53.7% 
females) from 11,395 families. Of these families, those at higher risk of developing T2DM 
(further mentioned as “high-risk families”) were identified. A family was identified as “high 
risk” if at least one parent had FINDRISC ≥10, considering the young age of the participants. 
Following this first screening via school setting, all the parents and/or grandparents of the 
“high-risk families”, irrespectively of their individually calculated FINDRISC, were invited to 
undergo a more detailed assessment (second screening) delivered in local community 
centers or during home visits (in Belgium).  
From the identified “high-risk families”, 3,148 parents from 2,535 families underwent the 
second screening. Of these, 83 (2.64%) participants were excluded from the current analysis 
because of previously diagnosed diabetes, 429 (13.6%) participants due to missing FPG data, 
117 (3.72%) participants due to incomplete information to calculate FINDRISC and 403 
(12.8%) participants due to missing other questionnaire or measurement data.  
In all countries, measurements were conducted by thoroughly trained research assistants, 
using standardized protocols and calibrated equipment. Recruitment started on January 
2016 and measurements were conducted between April-June and for Finland, Hungary and 
Bulgaria were extended during August-September 2016. 
2.3. Measures 
Questionnaire data: During the first screening, all parents were requested to complete the 
most recent version of the FINDRISC questionnaire, which consists of eight scored questions 
that cover the well-known risk factors of T2DM, i.e. age, body mass index (BMI), waist 
circumference (WC), daily physical activity, daily consumption of vegetables and fruits/ 
berries, use of antihypertensive medication, history of high blood glucose, and family history 
of diabetes [33]. The total score indicates the individual’s 10-year risk of developing T2DM 
and ranges from 0 to 26, as follows: <7 (low), 7-11 (slightly elevated), 12-14 (moderate), 15-
20 (high) and >20 (very high). In order to facilitate the assessment of WC, a paper measuring 
waist tape was provided to all participants. Standardized questionnaires were also used to 
collect data related to participants’ sociodemographics. 
Anthropometry: Body weight and height were measured in light clothing and without shoes 
to the nearest 0.1kg and 0.1cm respectively, and WC was measured midway between the 
lowest rib margin and the iliac crest to the nearest 0.1cm. Portable equipment was used (for 
weight: digital scales, for height: telescopic stadiometers, for WC: non-elastic tapes). BMI 
and WC were classified based on the World Health Organization (WHO) criteria [34]. 
Blood pressure measurement: Blood pressure was measured on the right arm, in a sitting 
position using electronic sphygmomanometers (OMRON M6 or OMRON M6 AC) after five 
minutes of rest, on three occasions, at one minute interval.  
Blood indices: Blood samples were drawn in the morning after overnight fasting (duration: 
eight hours or longer). FPG and serum total and high-density lipoprotein (HDL) cholesterol 
and triglyceride levels were analyzed in accredited laboratories, using similar enzymatic 
assays in all study centers. Low-density lipoprotein (LDL) cholesterol was calculated using the 
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Friedewald formula [35]. Participants without previously diagnosed diabetes were classified 
according to the WHO criteria [36], as: normal (FPG<6.1mmol/L), prediabetes (FPG 6.1-
6.9mmol/L) and T2DM (FPG≥7.0mmol/L). Dysglycaemia was defined as the presence of 
prediabetes or T2DM. 
2.4. Ethics statement 
The Feel4Diabetes-study adhered to the Declaration of Helsinki and the conventions of the 
Council of Europe on human rights and biomedicine. All participating countries obtained 
ethical clearance from the relevant ethical committees and local authorities. All participants 
gave their written informed consent prior to their enrolment in the study. 
2.5. Statistical analysis 
In the current analysis the participating countries were grouped to country categories as: 
HICs (Belgium-Finland), HICs under austerity measures (Greece-Spain) and LMICs (Bulgaria- 
Hungary). Descriptive data on participants’ characteristics are presented as means± standard 
deviations or percentages for continuous or categorical values, respectively. For between-
group comparisons, One-Way Analysis of Variance or Kruskall-Wallis was used for 
continuous variables, while the Pearson's Chi-square test was used to compare percentages. 
Receiver operating characteristic (ROC) analysis was used to assess the accuracy of the 
FINDRISC in detecting undiagnosed T2DM and dysglycaemia. The area under the ROC curves 
(AUC-ROCs) were plotted, while sensitivity (Se), specificity (Sp), positive predictive value 
(PPV) and negative predictive value (NPV) were calculated for FINDRISC values from 11 to 
16. The optimal cut-offs were determined by the point with the shortest distance to (0,1) in 
the ROC curve that maximizes the Se and Sp of the test. The distance for each observed cut-
off was calculated as the square root of [(1-Se)2 + (1-Sp)2] [37].  
Multivariate logistic regression models were constructed to estimate the association of 
FINDRISC value and its separate components with undiagnosed T2DM and dysglycaemia. 
These analyses were adjusted for potential confounders (sex, educational level and country 
category). All statistical tests were two-tailed and the level of statistical significance was set 
at P<0.05. The statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS Inc., Chicago, IL, USA), version 21.0 and the MedCalc (MedCalc Software 
bvba, Ostend, Belgium), version 18.6. 
3. Results 
Table 1 presents the descriptive characteristics of the 2,116 participants, stratified by 
country category. Participants were aged 41.1±5.48 years and 67.3% were women. The 
overall prevalence of unemployment was 5.1%, higher in HICs under austerity measures 
compared with HICs and LMICs (8.4% vs. 2.5% and 0.7%, respectively, P<0.05). About one 
quarter of participants had less than 12 years of education (22.9%) and were current 
smokers (25.9%), with these percentages being statistically significant lower in HICs 
compared with other country categories. According to FPG and the WHO criteria, the overall 
prevalence of undiagnosed T2DM was 1.2%, without significant differences among country 
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categories, while for prediabetes it was 5.6%, higher in HICs compared with LMICs (8.0% vs. 
3.5%, P<0.05). In the total sample, mean FINDRISC value was 10.2±4.06 (range 0-22), lower 
in LMICs compared with HICs and HICs under austerity measures (8.35±4.71 vs. 10.5±3.70 
and 10.8±3.70, respectively, P<0.05). Statistically significant differences were observed 
among country categories in the percentages of FINDRISC components. A higher percentage 
of participants in HICs had positive history of high blood glucose or family history of 
diabetes, while a lower percentage of participants in HICs under austerity measures 
belonged to the younger age categories, was physically active for at least 30 minutes daily 
and consumed vegetables and fruits/berries every day. Regarding LMICs, a higher 
percentage of participants belonged to lower categories of BMI and WC and was under 
antihypertensive medication. 
Table 2 presents the clinical characteristics of study participants across three FINDRISC 
categories (values: 0-11, 12-14, 15-26). As expected, age, prevalence of obesity and central 
obesity (defined as WC higher than 88cm or 102cm for women and men, respectively), but 
also blood pressure, FPG, cholesterol and triglyceride levels increased with greater FINDRISC 
(P<0.05 for all indices). A marked increase in the prevalence of undiagnosed T2DM and 
prediabetes was observed as FINDRISC values increased (P<0.001). Indicatively, in 
participants with FINDRISC≥15, the prevalence of undiagnosed T2DM and prediabetes was 
5.1% and 10.7%, respectively. 
The AUC-ROC for detecting undiagnosed T2DM (Figure 1A) was 0.824 (95% CI:0.755-0.893) 
for the total sample; 0.839 (95% CI:0.643-1.000) for HICs, 0.794 (95% CI:0.693-0.895) for 
HICs under austerity measures and 0.882 (95% CI:0.813-0.951) for LMICs. The AUC-ROC for 
detecting dysglycaemia (Figure 1B) was 0.663 (95% CI:0.615-0.710) for the total sample, 
0.656 (95% CI:0.579-0.733) for HICs, 0.631 (95% CI:0.559-0.702) for HICs under austerity 
measures and 0.735 (95% CI:0.617-0.854) for LMICs. No statistically significant differences in 
the AUC-ROCs were found among country categories for both outcomes (P>0.05 for all 
pairwise comparisons). Table 3 shows the FINDRISC characteristics (Se, Sp, PPV, NPV), using 
different cut-offs for identifying undiagnosed T2DM or dysglycaemia. The optimal cut-off for 
undiagnosed T2DM was ≥14 for the total sample (Se=68.0%; Sp=81.7%) and for LMICs 
(Se=71.4%; Sp=87.8%), ≥15 for HICs (Se=83.3%; Sp=86.9%) and ≥12 for HICs under austerity 
measures (Se=83.3%; Sp=61.1%). Regarding dysglycaemia, the optimal cut-off was ≥12 for 
the total sample (Se=58.3%; Sp=65.7%), as well as for HICs (Se=54.5%; Sp=64.8%) and for 
HICs under austerity measures (Se=59.7%; Sp=62.0%), while ≥11 for LMICs (Se=72.7%; 
Sp=70.2%). 
Results from logistic regressions showed significant associations of the FINDRISC with 
undiagnosed T2DM and dysglycaemia. One unit increase in the FINDRISC value was 
associated with a 35.6% (95% CI:22.0%-50.8%) increased odds of having undiagnosed T2DM 
and an 18.3% (95% CI:12.8%-24.1%) increased odds of having dysglycaemia, after adjusting 
for sex, educational level and country category (data not shown). Multivariate logistic 
regression analyses, as presented in Table 4, revealed the variables most strongly associated 
with undiagnosed T2DM to be BMI higher than 30kg/m2 (OR=2.82; 95% CI:1.04-7.66), 
regular use of antihypertensive medication (OR=2.63; 95% CI:1.03-6.69) and history of high 
blood glucose (OR=6.23; 95% CI:2.57-15.1). Significant associations were also observed 
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between dysglycaemia and BMI higher than 30kg/m2 (OR=1.80; 95% CI:1.18-2.74) and 
history of high blood glucose (OR=3.89; 95% CI: 2.60-5.83). 
4. Discussion 
The increasing prevalence of T2DM emphasizes the need to develop and implement better 
strategies for its early diagnosis and prevention. A simple first-level screening for 
prediabetes and T2DM through the use of non-laboratory and valid risk scores, followed by 
glycaemia testing for those individuals having a score considered high can be a cost-effective 
and practical method [12, 13, 18, 38]. As part of the Feel4Diabetes-study, we assessed the 
accuracy of the FINDRISC in detecting undiagnosed T2DM and dysglycaemia among 
vulnerable groups in Europe, highlighting the need to prioritize these populations to close 
the gap in health and social inequalities. Given the variability in the current population 
characteristics, AUC-ROCs and optimal cut-offs were also compared and provided separately 
for HICs (Belgium-Finland), HICs under austerity measures (Greece-Spain) and LMICs 
(Bulgaria-Hungary).  
In the current study, including a population of pre-selected adults with increased T2DM risk 
and/or their spouses irrespectively of their individual risk, the FINDRISC was found to 
perform reasonably well in identifying undiagnosed T2DM (AUC-ROC for the total sample: 
0.824; for HICs: 0.839; for HICs under austerity measures: 0.794; for LMICs: 0.882). These 
figures are in accordance with those obtained from other European countries so far, ranging 
from 0.62 to 0.81 [19-26]. Regarding dysglycaemia, the diagnostic accuracy of the FINDRISC 
was fair (AUC-ROC for the total sample: 0.663; for HICs: 0.656; for HICs under austerity 
measures: 0.631; for LMICs: 0.735), also comparable with the results of relevant studies, 
ranging from 0.52 to 0.72 [20, 21, 23-26]. As no statistically significant differences were 
observed among country categories in our study, it seems that the FINDRISC could be used 
as an equally accurate screening tool among the different vulnerable groups across Europe. 
To be used as an initial screening tool, a risk score should have a sufficient proportion of 
individuals correctly identified as diseased (high Se) and rule out those without the disease 
with high probability (high NPV) [39]. In the total sample, using an optimal FINDRISC cut-off 
≥14 and ≥12, the FINDRISC was able to identify 68% of those with undiagnosed T2DM and 
58.3% of those with dysglycaemia, respectively. The corresponding NPVs for these cut-offs 
were 99.5% and 95.6%. The cut-offs for undiagnosed T2DM found in the current study are 
close to those reported by other studies from Southern [20, 23, 25], Central [22] and Eastern 
Europe [26], but higher than those suggested by the FINRISK surveys [19, 24] and the IGLOO 
study [21], while among the studies that also examined dysglycaemia, lower [21, 25, 26] and 
higher [20, 23] cut-offs have been provided. Furthermore, different optimal cut-offs were 
found for each country category for detecting undiagnosed T2DM and dysglycaemia, 
respectively: ≥15 and ≥12 for HICs; ≥12 for both conditions for HICs under austerity 
measures; and ≥14 and ≥11 for LMICs. The different optimal cut-offs observed for each one 
of the subpopulations could be due to differences among country categories in the 
prevalence of T2DM or dysglycaemia, as well as in several other population characteristics 
(e.g. lifestyle, socio-demographic factors). Correspondingly, Zhang et al. [31] identified 
  
9 
 
different optimal cut-offs by racial/ ethnic group among U.S. population. These findings 
support the application of different optimal cut-offs to different subgroups, highlighting also 
the rationality of evaluating the FINDRISC before applying it to a specific population. 
As there are several methodological differences between the studies that have previously 
validated the FINDRISC, the current study should be compared to these with caution. 
Compared to previous studies conducted in Europe so far, our study sample comprised of 
younger adults (parents of primary-school children), apparently healthy that were recruited 
via the school-setting, using a systematic community-based approach. Furthermore, the gold 
standard used for the evaluation of the FINDRISC and the relevant diagnostic criteria may 
also play a role. In the majority of studies, the OGTT and/or FPG were considered the gold 
standard and the WHO criteria were used for T2DM and/or prediabetes diagnosis [19, 21-24, 
26], while three recent studies used OGTT, FPG and HbA1c methods [20, 25, 31]. Two of 
these studies [20, 25] examined the use of OGTT, FPG and HbA1c separately in detecting 
undiagnosed T2DM and dysglycaemia in Spanish populations. Based on FPG and the 
American Diabetes Association criteria [37], in the study of Salinero-Fort et al. [25], the AUC-
ROC for undiagnosed T2DM was 0.68 with optimal cut-off ≥13, while the AUC-ROC for 
dysglycaemia was 0.60 with optimal cut-off ≥11. Respectively, Costa et al. [20] proposed an 
optimal cut-off ≥14 for both conditions and concluded that OGTT and FPG have better 
overall discriminatory power than HbA1c. Last but not least, methodological differences 
regarding the FINDRISC data should be also taken into consideration, as in some studies 
shortened versions have been used [19, 21, 22], while in others the questionnaire was not 
self-administrated [20, 31]. 
It has been proposed that a simplified version of the FINDRISC could improve its efficiency. 
Simplified tools applied in Germany (including age, BMI, history of high blood glucose) [22] 
and Spain (including BMI, use of antihypertensive medication, history of high blood glucose) 
[25] were found to perform equally and better than the FINDRISC, respectively, in detecting 
undiagnosed T2DM. In the current study, three out of eight individual FINDRISC variables 
were significantly associated with undiagnosed T2DM (i.e. BMI, use of antihypertensive 
medication, history of high blood glucose), while two of those (i.e. BMI, history of high blood 
glucose) were significantly associated with dysglycaemia. In the original FINDRISC, the 
history of high blood glucose was the most powerful predictor of T2DM, whereas diet and 
physical activity components were included in the risk score to emphasize their importance, 
although they did not contribute much to the model’s predictive power [19]. It should also 
be noted that the commonest missing item from the FINDRISC form in our study was WC, 
which is probably not frequently recognized as a risk factor for T2DM by the general 
population, as previously suggested [24]. Therefore, for rapid-screening purposes, a shorter, 
less time-consuming version of the FINDRISC, including the components most strongly 
associated with T2DM, may be preferable, while further validation studies are required to 
this direction.  
Potential limitations of our study include the fact that although it is based on a community 
cohort, the results may not be applicable to the general population, especially in the case of 
HICs and the HICs under austerity measures, where vulnerable groups were targeted. 
Furthermore, only adults from the high-risk families were invited to take part in the 
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measurements, therefore our study population does not represent the whole background 
population, which might have effect on the diagnostic indicators. Moreover, the large study 
sample and design did not allow us to conduct OGTT, thus T2DM and prediabetes diagnosis 
were derived only by the use of FPG. However, this method has been also solely used in 
relevant studies assessing the diagnostic accuracy of the FINDRISC [20, 25], while in a recent 
study, 63% of people with undiagnosed T2DM and 62% of those with prediabetes were 
identified by using FPG [40]. Another limitation could be that the diagnosis was not 
confirmed by repeated glucose testing, but this condition is never fulfilled in epidemiological 
studies. On the other hand, the large and pan-European study sample can be considered as a 
major strength, while data were collected by well-trained researchers, following 
standardized protocols and procedures across all centers. Demographic characteristics and 
several socioeconomic data were also available in the current study, allowing us to further 
evaluate the FINDRISC in different vulnerable groups. 
5. Conclusions 
The results of the current study add to the available literature with data retrieved from 
vulnerable groups in a large-scale European cohort and provide novel information on the 
ability of the FINDRISC to identify individuals with T2DM and dysglycaemia that were 
unaware of their condition. Our data further support the use of the FINDRISC as a useful self-
administrated tool and the first step in screening large multinational populations and 
identifying individuals primarily with undiagnosed T2DM but also with dysglycaemia. In the 
study population, a cut-off ≥14 found to be the most suitable value for identifying 
undiagnosed T2DM, while a cut-off ≥12 proved to be optimal for the detection of 
dysglycaemia. The different cut-offs identified for each country category could be also taken 
into consideration in the practical application, while the use of any simplified version of the 
FINDRISC could also be considered for systematic population screening. These findings could 
guide future public health actions to prioritize diabetes screening initiatives in vulnerable 
groups and tackle the health and social inequality-related issues.  
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Table 1. Descriptive characteristics of the study population by country category 
 
Total sample 
(n=2,116) 
 
High-Income 
Countries 
(Belgium-
Finland) 
 (n=610) 
 High-Income 
Countries under 
austerity 
measures 
(Greece-Spain) 
 (n=1,074) 
 Low/Middle-
Income 
Countries 
(Bulgaria-
Hungary) 
(n=432) 
 
P-
value* 
Age (years) 41.1 (5.48)  40.2 (5.58)a  42.3 (5.36)a,b  39.6 (4.97)b  <0.001 
Females, % (n) 67.3 (1,425)  69.0 (421)a,b  62.6 (672)a,c  76.9 (332)b,c  <0.001 
Occupation, % (n)          
Unemployed 5.1 (108)  2.5 (15)a  8.4 (90)a,b  0.7 (3)b  <0.001 
Stay at home parent 12.5 (265)  7.5 (46)a,b  15.1 (162)a  13.2 (57)b   
Work part- time 11.6 (245)  15.9 (97)a,b  10.8 (116)a  7.4 (32)b   
Other ¥ 70.8 (1,498)  74.1 (452)a  65.7 (706)a,b  78.7 (340)b   
Educational level, % (n)          
<12 years 22.9 (485)  16.2 (99)a  27.1 (291)a  22.0 (95)  <0.001 
≥12 years 77.1 (1,631)  83.8 (511)a  72.9 (783)a  78.0 (337)   
Smoking, % (n)          
Never 45.2 (957)  55.4 (338)a,b  43.2 (464)a,c  35.7 (155)b,c  <0.001 
Ex-smoker 28.9 (611)  33.6 (205)a,b  27.6 (296)a  25.4 (110)b   
Current smoker 25.9 (548)  11.0 (67)a,b  29.2 (314)a,c  38.8 (167)b,c   
Undiagnosed T2DM, % (n) 1.2 (25)  1.0 (6)  1.1 (12)  1.6 (7)  0.620 
Prediabetes, % (n) 5.6 (119)  8.0 (49)a  5.1 (55)  3.5 (15)a  0.019 
FINDRISC value 10.2 (4.06)  10.5 (3.70)a  10.8 (3.70)b  8.35 (4.71)a,b  <0.001 
FINDRISC categories, % (n)          
<7 16.4 (346)  12.6 (77)a  11.7 (126)b  33.1 (143)a,b  <0.001 
7-11 47.7 (1010)  50.5 (308)a  48.9 (525)b  41.0 (177)a,b   
12-14 23.1 (488)  23.1 (141)  25.1 (270)a  17.8 (77)a   
15-20 12.4 (263)  13.4 (82)a  13.9 (149)b  7.4 (32)a,b   
>20 0.4 (9)  0.2 (2)  0.4 (4)  0.7 (3)   
FINDRISC components          
Age          
<45 years 76.0 (1,609)  80.2 (489)a  70.0 (752)a,b  85.2 (368)b   <0.001 
45-54 years 23.1 (488)  19.0 (116)a  28.8 (309)a,b  14.6 (63)b   
55-64 years 0.8 (17)  0.5 (3)  1.2 (13)  0.2 (1)   
>64 years 0.1 (2)  0.3 (2)  0.0 (0)  0.0 (0)   
BMI          
<25kg/m2 33.6 (710)  29.8 (182)a  30.4 (327)b  46.5 (201)a,b  <0.001 
25-30kg/m2 37.3 (789)  39.8 (243)a  38.5 (413)b  30.8 (133)a,b   
>30kg/m2 29.2 (617)  30.3 (185)a  31.1 (334)b  22.7 (98)a,b   
Waist circumference          
F:<80cm, M:>94cm 13.7 (289)  7.4 (45)a  10.5 (113)b  30.3 (131)a,b  <0.001 
F:80-88cm, M:94-102cm 33.6 (711)  32.1 (196)  34.9 (375)  32.4 (140)   
F:>88cm, M:>102cm 52.7 (1,116)  60.5 (369)a  54.6 (586)b  37.3 (161)a,b   
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Physical activity (30min/day)          
Yes 63.4 (1,342)  71.1 (434)a  55.0 (591)a,b  73.4 (317)b  <0.001 
No 36.6 (774)  28.9 (176)a  45.0 (483)a,b  26.6 (115)b   
Vegetables, fruit/berries 
consumption 
 
 
 
 
 
 
 
 
 
Every day 68.8 (1,456)  80.0 (493)a  58.7 (630)a,b  77.1 (333)b  <0.001 
Not every day 31.2 (660)  19.2 (117)a  41.3 (444)a,b  22.9 (99)b   
Antihypertensive medication          
No 88.2 (1,867)  90.3 (551)a  90.9 (976)b  78.7 (340)a,b  <0.001 
Yes 11.8 (249)  9.7 (59)a  9.1 (98)b  21.3 (92)a,b   
History of high blood glucose           
No 74.9 (1,584)  68.4 (417)a,b  75.7 (813)a,c  81.9 (354)b,c  <0.001 
Yes 25.1 (532)  31.6 (193)a,b  24.3 (261)a,c  18.1 (78)b,c   
Family members with 
diabetes 
 
 
 
 
 
 
 
 
 
No 32.7 (691)  25.9 (158)a,b  33.1 (355)a,c  41.2 (178)b,c  <0.001 
Grandparent, aunt, uncle or 
first cousin 
39.6 (838) 
 
40.2 (245)a 
 
23.2 (249)a 
 
21.5 (93) 
 
 
Parent, brother, sister or 
own child 
27.7 (587) 
 
33.9 (207)a,b 
 
43.8 (470)a 
 
37.3 (161)b 
 
 
Data are means (SD) except where noted otherwise. 
Figures sharing the same superscript letters differentiate significantly from each other. 
*P-values indicate the significance of the differences among country categories. 
¥ Other includes work full-time, full-time education and retired. 
BMI: Body mass Index; FINDRISC: Finnish Diabetes Risk Score; F: females; M: males; T2DM: Type 2 diabetes mellitus  
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Table 2. Clinical characteristics of the study population by FINDRISC category 
  FINDRISC 0-11 
(n=1,356) 
 FINDRISC 12-14 
(n=488) 
 FINDRISC 15-26 
(n=272) 
 
P-value* 
FINDRISC value 7.96 (2.98)a,b  12.8 (0.82)a  16.7 (1.72)b,c  <0.001 
Females, % (n) 67.5 (915)  63.3 (309)a  73.9 (201)a  0.012 
Age (years) 40.6 (5.23)a,b  41.9 (5.41)a  42.4 (6.38)b  <0.001 
Weight status, % (n)        
Underweight & Normal- 
weight 
38.5 (522)a,b  11.9 (58)a  10.3 (28)b  <0.001 
Overweight 36.8 (499)a  35.7 (174)b  26.5 (72)a,b   
Obese 24.7 (256)a,b  52.5 (256)a,c  63.2 (172)b,c   
Waist Circumference, % (n)        
F:<80cm, M:>94cm 30.5 (414)a,b  8.8 (43)a  4.8 (13)b  <0.001 
F:80-88cm, M:94-102cm 28.8 (390)a,b  20.5 (100)a,c  13.2 (36)b,c   
F:>88cm, M:>102cm 40.7 (552)a,b  70.7 (345)a,c  82.0 (223)b,c   
Systolic BP (mmHg) 115.8 (16.2)a,b  120.5 (16.7)a  121.1 (17.0)b  <0.001 
Diastolic BP (mmHg) 77.0 (11.0)a,b  80.3 (11.1)a  80.9 (12.1)b  <0.001 
Fasting glucose (mmol/l) 5.15 (0.59)a,b  5.34 (0.88)a,c  5.55 (0.76)b,c  <0.001 
Total cholesterol (mmol/l) 4.96 (0.94)a,b  5.10 (1.02)a  5.12 (0.97)b  0.002 
LDL cholesterol (mmol/l) 3.05 (0.83)a,b  3.19 (0.89)a  3.22 (0.81)b  <0.001 
HDL cholesterol (mmol/l) 1.41 (0.37)a,b  1.33 (0.33)a  1.30 (0.32)b  <0.001 
Fasting Triglycerides (mmol/l) 1.09 (0.63)a,b  1.26 (0.71)a  1.31 (0.69)b  <0.001 
Undiagnosed T2DM, % (n) 0.3 (4)a,b  1.4 (7)a,c  5.1 (14)b,c  <0.001 
Prediabetes, % (n) 4.1 (56)a,b  7.0 (34)a  10.7 (29)b  <0.001 
Data are means (SD) except where noted otherwise. 
Figures sharing the same superscript letters differentiate significantly from each other. 
*P-values indicate the significance of the differences among FINDRISC categories: 0-11 (low and slightly elevated risk), 12-14 
(moderate risk), 15-26 (high and very high risk) 
BP: Blood pressure; FINDRISC: Finnish Diabetes Risk Score; F: females; M: males; LDL: Low-density lipoprotein; HDL: High-density 
lipoprotein; T2DM: Type 2 diabetes mellitus 
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Table 3. Characteristics of FINDRISC using different cut-offs for detecting undiagnosed diabetes and dysglycaemia  
 
Total sample 
(n=2,116) 
 
High-Income Countries  
(Belgium-Finland) 
(n=610) 
 High-Income Countries under 
austerity measures 
(Greece-Spain) 
(n=1,074) 
 
Low/Middle-Income Countries 
(Bulgaria-Hungary) 
(n=432) 
Cut-off  Se (%) Sp (%) PPV (%) NPV (%)  Se(%) Sp (%) PPV (%) NPV (%)  Se (%) Sp (%) PPV (%) NPV (%)  Se (%) Sp (%) PPV (%) NPV (%) 
Undiagnosed T2DM   
11 92.0 54.6 2.36 99.8  83.3 52.5 1.71 99.7  91.7 49.9 2.03 99.8  100 69.2 5.07 100.0 
12 84.0 64.7 2.76 99.7  83.3 63.6 2.22 99.7  83.3 61.1 2.36 99.7  85.7 75.1 5.36 99.7 
13 72.0 75.0 3.33 99.6  83.3 74.5 3.15 99.8  66.7 72.4 2.66 99.5  71.4 82.4 6.25 99.4 
14 68.0 81.7 4.26 99.5  83.3 81.1 4.20 99.8  58.3 79.7 3.14 99.4  71.4 87.8 8.77 99.5 
15 56.0 87.7 5.15 99.4  83.3 86.9 5.95 99.8  50.0 86.2 3.92 99.3  42.9 92.5 8.57 99.0 
16 40.0 91.8 5.53 99.2  66.7 91.6 7.27 99.6  33.3 90.9 3.96 99.2  28.6 94.6 8.00 98.0 
Dysglycaemia 
11 66.0 55.5 9.76 95.7  65.5 53.9 12.3 94.0  64.2 50.3 7.92 95.5  72.7 70.2 11.6 98.0 
12 58.3 65.7 11.1 95.6  54.5 64.8 13.3 93.5  59.7 62.0 9.46 95.9  63.6 76.1 12.5 97.5 
13 47.9 76.1 12.8 95.2  43.6 75.7 15.1 93.1  47.8 73.3 10.6 95.5  59.1 83.7 16.3 97.4 
14 39.6 82.7 14.3 94.9  40.0 82.5 18.5 93.3  37.3 80.3 11.2 95.1  45.5 88.5 17.5 96.8 
15 29.9 88.4 15.8 94.5  32.7 88.1 21.4 92.3  26.9 86.6 11.8 94.7  31.8 93.2 20.0 96.2 
16 25.0 92.6 19.9 94.4  27.3 92.8 27.3 92.8  22.4 91.5 14.9 94.7  27.3 95.4 24.0 96.1 
Data are percentages (%). 
Figures in bold indicate optimal cut-offs. 
FINDRISC: Finnish Diabetes Risk Score; T2DM: Type 2 diabetes mellitus; Se: sensitivity; Sp: Specificity; PPV: Positive Predictive Value; NPV: Negative Predictive Value
  
19 
 
 
 
Table 4. Associations between the FINDRISC components and undiagnosed diabetes or 
dysglycaemia in the total sample (n=2,116) 
 Undiagnosed T2DM   Dysglycaemia  
 OR (95% CI)  OR (95% CI) 
Age      
Under 45 years 1.00   1.00  
Over 45 years 2.31 (0.97-5.48)  1.68 (1.14-2.47) 
BMI      
<30kg/m2 1.00   1.00  
>30kg/m2 2.82 (1.04-7.66)  1.80 (1.18-2.74) 
Waist circumference      
F:<88cm, M:<102cm 1.00   1.00  
F:>88cm, M:>102cm 1.48 (0.51-4.30)  1.35 (0.88-2.08) 
Physical activity (30min/day)      
Yes 1.00   1.00  
No 0.65 (0.26-1.61)  0.91 (6.63-1.34) 
Vegetables, fruit/berries consumption      
Every day 1.00   1.00  
Not every day 1.31 (0.54-3.17)  1.10 (0.75-1.62) 
Antihypertensive medication      
No 1.00   1.00  
Yes 2.63 (1.03-6.69)  0.970 (0.58-1.62) 
History of high blood glucose       
No 1.00   1.00  
Yes 6.23 (2.57-15.1)  3.89 (2.60-5.83) 
Family members with diabetes      
No 1.00   1.00  
Grandparent, aunt, uncle or first cousin 1.13 (0.33-3.93)  0.99 (0.61-1.60) 
Parent, brother, sister or own child 2.78 (1.00-7.74)  1.35 (0.88-2.06) 
Multivariate logistic regression models adjusted for sex, educational level and country category. 
BMI: Body mass Index; F: females; M: males; T2DM: Type 2 diabetes mellitus; OR: Odds Ratio; 95% CI: 
95% Confidence interval 
 
Figure 1. Receiver operating characteristic (ROC) curves for detecting (A) undiagnosed diabetes (B) 
dysglycaemia (AUC-ROC: Area under the ROC curve; HICs: High-income countries; LMICs: Low/middle-income 
countries) 
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